Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL
Status:
Terminated
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
IMMU-114 will be studied at different dose schedules and dose levels in order to assess the
highest dose safely tolerated. IMMU-114 will be administered subcutaneously (under the skin).
IMMU-114 will be given 1-2 times weekly for 3 weeks followed by one week of rest. This is
considered one cycle. Treatment cycles will be repeated until toxicity or worsening of
disease.